ArticleCancer science2025

Engineered EVs-Mediated miR-222 Targeting PTEN/FN1 Axis Reverses Anthracycline Resistance in HER2-Negative Breast Cancer.

Sujin Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.